Acta Crystallographica Section C Crystal Structure Communications

ISSN 0108-2701

trans-Tetraaquabis(5-fluorouracil-1-acetato-O)zinc(II) tetrahydrate

Chang-Zheng Li et al.

Electronic paper

This paper is published electronically. It meets the data-validation criteria for publication in Acta Crystallographica Section C. The submission has been checked by a Section C Co-editor though the text in the 'Comments' section is the responsibility of the authors.

© 2000 International Union of Crystallography • Printed in Great Britain - all rights reserved

electronic papers

Acta Crystallographica Section C **Crystal Structure** Communications ISSN 0108-2701

trans-Tetraaquabis(5-fluorouracil-1acetato-O)zinc(II) tetrahydrate

Chang-Zheng Li,^a Liu-Fang Wang,^a* Yi-Zhi Li,^a Chun-Gu Xia^b and Rong-Bin Dai^c

^aState Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, Gansu 730000, People's Republic of China, ^bState Key Laboratory of Oxo-Synthesis and Selective Oxidation, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000, People's Republic of China, and ^cState Key Laboratory of Drug Research in Shanghai, Shanghai 200031, People's Republic of China

Correspondence e-mail: llyyjz@mail.gs.cninfo.net

Received 11 July 2000 Accepted 27 July 2000

Data validation number: IUC0000203

In the title complex, $[Zn(C_6H_4FN_2O_4)_2(H_2O)_4] \cdot 4H_2O$, the Zn atom is located at a center of symmetry and has a distorted octahedral geometry, with Zn-O distances in the range 2.052 (2)–2.181 (2) Å. Hydrogen bonds involving the water molecules make up a three-dimensional network.

Comment

5-Fluorouracil is a normal antitumor drug used in clinics and it can be used to treat breast cancer, gastric carcinoma and bladder cancer. However, the toxic side effects, such as marrow inhibition, limits its wider applicability. A search for highly effective and low toxicity novel antitumor drugs is an active research field and an urgent task for scientists. In order to reduce the side effects, many derivatives of 5-fluorouracil have been synthesized and some compounds have better biological activity. 5-Fluoro-1-uracilacetic acid (5-FUAA) is a member of this family. Its metal complexes had been reported.



However, assignment of the coordination mode are very confused due to the fact that it contains several potential donor atoms; it is therefore necessary to clarify the structures of these complexes.

5-FUAA was synthesized according to literature methods (Tada, 1975) and the title complex, (I), was synthesized by a new method. The physiochemical properties were characterized by elemental analysis, TG-DTA, IR and X-ray diffraction.

The antitumor activity against K562 and L1210 was investigated. In the title complex, the Zn atom is located in a center of symmetry and has a distorted octahedral geometry with Zn-O distances in the range 2.052 (2)–2.181 (2) Å. Because there are four coordinated water and four crystal water molecules, three intramolecular hydrogen bonds and nine intermolecular hydrogen bonds are formed (Table 2). These hydrogen bonds make up of a network, which may be the reason for the stability of the crystal.

Experimental

The ligand 5-fluorouracil-1-acetic acid (5-FUAA) was prepared according to literature methods (Tada, 1975). The complex was synthesized as follows: a water-ethanol (1:1) solution of 5-FUAA (1 mmol, 0.1891 g) was added to an aqueous ethanol (1:1) solution of $Zn(OAc)_2 \cdot 2H_2O$ (0.05 mmol, 0.1096 g) with stirring. The mixture was stirred continuously for 8 h and the white precipitate obtained was suction-filtrated and washed with 50% ethanol and finally dried in vacuo. Colorless crystals suitable for diffraction studies were obtained from an aqueous ethanol solution by slow evaporation.

Crystal data

,	
$[Zn(C_{6}H_{4}FN_{2}O_{4})_{2}(H_{2}O)_{4}]\cdot 4H_{2}O$ $M_{r} = 583.72$ Monoclinic, $P2_{1}/c$ a = 8.571 (2) Å b = 12.102 (2) Å c = 10.814 (2) Å $\beta = 91.53$ (2)° V = 1121.3 (4) Å ³ Z = 2	$D_x = 1.729 \text{ Mg m}^{-3}$ Mo K\alpha radiation Cell parameters from 25 reflections $\theta = 16.12-16.92^{\circ}$ $\mu = 1.198 \text{ mm}^{-1}$ T = 293 (2) K Prismatic, colorless $0.35 \times 0.15 \times 0.10 \text{ mm}$
Data collection	
Enraf-Nonius CAD-4 diffract- ometer $\omega/2\theta$ scans Absorption correction: ψ scan (North <i>et al.</i> , 1968) $T_{\min} = 0.856$, $T_{\max} = 0.887$ 1986 measured reflections 1971 independent reflections 1804 reflections with $I > 2\sigma(I)$ '	R_{int} $\theta_{max} = 24.97^{\circ}$ $h = 0 \rightarrow 10$ $k = 0 \rightarrow 14$ $l = -12 \rightarrow 12$ 5 standard reflections every 390 reflections intensity decay: none
Refinement	
Refinement on F^2 $R[F^2 > 2\sigma(F^2)] = 0.030$ $wR(F^2) = 0.110$ S = 0.884 1971 reflections 160 parameters H-atom parameters constrained	$\begin{split} &w = 1/[\sigma^2(F_o^2) + (0.0200P)^2 \\ &+ 0.3500P] \\ &where \ P = (F_o^2 + 2F_c^2)/3 \\ (\Delta/\sigma)_{\rm max} < 0.001 \\ \Delta\rho_{\rm max} = 0.55 \ {\rm e} \ {\rm \AA}^{-3} \\ \Delta\rho_{\rm min} = -0.48 \ {\rm e} \ {\rm \AA}^{-3} \end{split}$
Table 1	
Selected geometric parameters (Å, °).	

Zn-O1 Zn-O3	2.0521 (17) 2.0668 (15)	Zn-O2	2.1806 (16)
$\begin{array}{c} 01 - Zn - O3^{i} \\ 01^{i} - Zn - O3^{i} \\ 01 - Zn - O3 \\ 01^{i} - Zn - O3 \\ 01 - Zn - O2^{i} \\ 01^{i} - Zn - O2^{i} \end{array}$	89.42 (7) 90.58 (7) 90.58 (7) 89.42 (7) 89.12 (7) 90.88 (7)	$\begin{array}{c} O3^{i} - Zn - O2^{i} \\ O3 - Zn - O2^{i} \\ O1 - Zn - O2 \\ O1^{i} - Zn - O2 \\ O3^{i} - Zn - O2 \\ O3 - Zn - O2 \end{array}$	86.58 (6) 93.42 (6) 90.88 (7) 89.12 (7) 93.42 (6) 86.58 (6)

Symmetry code: (i) 1 - x, -y, -z.

Table 2	
Hydrogen-bonding geometry (Å, °).

$D - H \cdot \cdot \cdot A$	D-H	$H \cdot \cdot \cdot A$	$D \cdots A$	$D - \mathbf{H} \cdot \cdot \cdot A$
N2-H2···O8	0.90	1.92	2.818 (3)	176
$O7-H7A\cdots O6$	0.96	1.89	2.847 (3)	180
$O8-H8A\cdots O7$	0.96	2.21	3.070 (3)	148
$O1-H1A\cdots F^i$	0.96	2.45	2.999 (3)	116
$O1-H1A\cdots O7^{ii}$	0.96	2.49	3.288 (3)	140
$O1-H1B\cdots O8^{ii}$	0.96	2.03	2.747 (2)	130
$O2-H2A\cdots O7^{iii}$	0.96	2.29	2.879 (3)	119
$O2-H2B\cdots O4^{iv}$	0.96	1.97	2.645 (2)	125
$O7 - H7B \cdot \cdot \cdot O1^{v}$	0.96	1.83	2.681(2)	146
$O7-H7B\cdots F^{vi}$	0.96	2.55	3.232 (3)	128
O8−H8A···O5 ^{vii}	0.96	2.40	2.890 (2)	111
$O8-H8B\cdots O4^{viii}$	0.96	1.98	2.651 (2)	125

Symmetry codes: (i) $x, \frac{1}{2} - y, z - \frac{1}{2}$; (ii) $1 - x, \frac{1}{2} + y, \frac{1}{2} - z$; (iii) $x, -\frac{1}{2} - y, z - \frac{1}{2}$; (iv) 1 - x, -y, -z; (v) 1 - x, -y, 1 - z; (vi) $1 - x, y - \frac{1}{2}, \frac{3}{2} - z$; (vii) $x, -\frac{1}{2} - y, \frac{1}{2} + z$; (viii) $2 - x, y - \frac{1}{2}, \frac{1}{2} - z$.

The positions of all H atoms were fixed geometrically and distances to H atoms were set by the refinement program (O-H/C-H = 0.96 Å and N-H = 0.90 Å).

Data collection: CAD-4 SDP/VAX (Enraf–Nonius, 1989); cell refinement: CAD-4 SDP/VAX; data reduction: TEXSAN (Molecular

Structure Corporation, 1989); program(s) used to solve structure: *SHELXS*97 (Sheldrick, 1997); program(s) used to refine structure: *SHELXL*97 (Sheldrick, 1997); software used to prepare material for publication: *SHELXL*97.

The work was supported by the China Innovation Center for Life Science and the Natural Science Foundation of Gansu Province (no. ZS991-A23-059-Y). We are grateful to Professor George M. Sheldrick of Göttingen University (Germany) for providing the *SHELXL*97 program.

References

Enraf–Nonius (1989). *CAD-4 SDP/VAX*. Delft Instruments X-ray Diffraction, PO Box 811, 2600 AV Delft, The Netherlands.

Molecular Structure Corporation (1989). *TEXSAN*. Version 5.0. MSC, 3200 Research Forest Drive, The Woodlands, TX 77381, USA.

North, A. C. T., Phillips, D. C. & Mathews, F. S. (1968). Acta Cryst. A24, 351–359.

Sheldrick, G. M. (1997). SHELXS97 and SHELXL97. University of Göttingen, Germany.

Tada, M. (1975). Bull. Chem. Soc. Jpn, 48, 3427-3428.